Galenica Ltd.

GALE

Equity

ISIN CH0360674466 / Valor 36067446

SIX Swiss Exchange (2026-02-20)

CHF 101.30-1.46%

Galenica Ltd.
UMushroom community rating:

4.00 1 votes No rating yet

NegativeNeutralPositive

About company

Galenica Ltd. is a prominent player in the Swiss healthcare market, operating a comprehensive network of over 20 business units. The company focuses on delivering seamless, efficient, and personalized healthcare solutions to meet the needs of patients and customers. In the 2024 financial year, Galenica reported a 4.7% increase in sales, achieving consolidated net sales of CHF 3,921.1 million. This growth allowed the company to outperform the market and expand its market share across its primary business areas. Galenica's strategic partnerships and robust network position it as a key contributor to the Swiss healthcare sector.

Summarized from source with an LLMView SourceSector: Healthcare

Key financials

Net sales CHF 3,921.1m (+4.7%); adjusted EBIT CHF 211.0m (5.4% of sales); profit from continuing operations CHF 183.7m (+10.9%); adjusted profit CHF 183.2m (+13.4%).

Dividend

Board proposes gross dividend CHF 2.30 per share (up 4.5% vs. prior year), split CHF 1.15 from retained earnings and CHF 1.15 from capital contribution reserves.

Segment performance

Products & Care: net sales CHF 1,700.2m (+3.9%), adjusted EBIT CHF 157.3m (9.2% margin). Logistics & IT: net sales CHF 3,241.4m (+5.3%), adjusted EBIT CHF 56.8m (1.8% margin) with strong EBIT improvement (+34.2% YoY).

Cash, investment and balance sheet

Free cash flow CHF 61.0m (+23.7%), adjusted cash flow from operations CHF 212.1m (+22.3%), investments (PPE & intangibles) CHF 72.8m. Shareholders’ equity CHF 1,551.8m (equity ratio 50.5%); adjusted net debt CHF 424.1m.

Operational & commercial drivers

Pharmacy network expansion: 12 acquisitions, 2 openings, 4 closures/mergers; organic pharmacy sales +2.7% driven by prescription demand. Verfora export growth +15.1%; Services for Professionals +7.5%; strong doctor’s segment growth +7.8%.

Digital, safety and strategic initiatives

HCI Solutions: ~369 million clinical decision support (CDS) checks in 2024 (+33%), supporting patient safety. Rollout of “Consultation plus” pharmacy service and ERP/warehouse improvements (Galexis), plus Health Supply (joint venture with Planzer) progressing as planned.

Sustainability & people

Report integrates TCFD recommendations; Ecovadis recognition for Alloga; energy and GHG metrics disclosed (energy ~70,914 MWh; direct & indirect emissions 11,485 tCO₂e). Employees ~7,971, FTE 6,119, with continued investment in training and new workplace initiatives (Swing Space).

Summarized from source with an LLMView Source

Key figures

24.0%1Y

35.1%3Y

68.8%5Y

Performance

18.3%1Y

15.8%3Y

17.4%5Y

Volatility